Skip to content

2022 Publications

  • Zanatta E, Huscher D, Ortolan A, Avouac J, Airò P, Balbir-Gurman A, Siegert E, Matucci Cerinic M, Cozzi F, Riemekasten G, Hoffmann-Vold AM, Distler O, Gabrielli A, Heitmann S, Hunzelmann N, Montecucco C, Morovic-Vergles J, Ribi C, Doria A, Allanore Y; EUSTAR collaborators. Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. Rheumatology (Oxford). 2022 Nov 28;61(12):4786-4796. doi: 10.1093/rheumatology/keac188. PMID: 35348643. (PDF)
  • Kuster S, Jordan S, Elhai M, Held U, Steigmiller K, Bruni C, Cacciapaglia F, Vettori S, Siegert E, Rednic S, Codullo V, Airo P, Braun-Moscovici Y, Hunzelmann N, Joao Salvador M, Riccieri V, Gheorghiu AM, Alegre Sancho JJ, Romanowska-Prochnicka K, Castellví I, Kötter I, Truchetet ME, López-Longo FJ, Novikov PI, Giollo A, Shirai Y, Belloli L, Zanatta E, Hachulla E, Smith V, Denton C, Ionescu RM, Schmeiser T, Distler JHW, Gabrielli A, Hoffmann-Vold AM, Kuwana M, Allanore Y, Distler O; EUSTAR collaborators. Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort. RMD Open. 2022 Nov;8(2):e002477. doi: 10.1136/rmdopen-2022-002477. PMID: 36328401. (PDF)
  • Elhai M, Sritharan N, Boubaya M, Balbir-Gurman A, Siegert E, Hachulla E, de Vries-Bouwstra J, Riemekasten G, Distler JHW, Rosato E, Del Galdo F, Mendoza FA, Furst DE, de la Puente C, Hoffmann-Vold AM, Gabrielli A, Distler O, Bloch-Queyrat C, Allanore Y; EUSTAR collaborators. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort. Lancet Rheumatol. 2022 Nov;4(11):e785-e794. doi: 10.1016/S2665-9913(22)00217-X. PMID: 38265945
  • Bruni C, Chung L, Hoffmann-Vold AM, Assassi S, Gabrielli A, Khanna D, Bernstein EJ, Distler O; EUSTAR and SCTC collaborators. High-resolution computed tomography of the chest for the screening, re-screening and follow-up of systemic sclerosis-associated interstitial lung disease: a EUSTAR-SCTC survey. Clin Exp Rheumatol. 2022 Oct;40(10):1951-1955. doi: 10.55563/clinexprheumatol/7ry6zz. PMID: 35819810. (PDF)
  • Liem SIE, Boonstra M, le Cessie S, Riccardi A, Airo P, Distler O, Matucci-Cerinic M, Caimmi C, Siegert E, Allanore Y, Huizinga TWJ, Toes REM, Scherer HU, de Vries-Bouwstra JK; EUSTAR collaborators. Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohorts. Lancet Rheumatol. 2022 Oct;4(10):e699-e709. doi: 10.1016/S2665-9913(22)00224-7. PMID: 38265968
  • Campochiaro C, Lazzaroni MG, Bruni C, Zanatta E, De Luca G, Matucci-Cerinic M. Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review. Ther Adv Musculoskelet Dis. 2022 Aug 22;14:1759720X221116408. doi: 10.1177/1759720X221116408. PMID: 36051631. (PDF)
  • Hughes M, Heal C, Henes J, Balbir-Gurman A, Distler JHW, Airò P, Müller-Ladner U, Hunzelmann N, Kerzberg E, Rudnicka L, Truchetet ME, Stebbings S, Tanaka Y, Hoffman-Vold AM, Gabrielli A, Distler O, Matucci-Cerinic M; EUSTAR Collaborators. Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort. Rheumatology (Oxford). 2022 Mar 2;61(3):1141-1147. doi: 10.1093/rheumatology/keab510. PMID: 34146098. (PDF)
  • Iudici M, Jarlborg M, Lauper K, Müller-Ladner U, Smith V, Allanore Y, Balbir-Gurman A, Doria A, Airò P, Walker UA, Riccieri V, Vonk MC, Gabrielli A, Hoffmann-Vold AM, Szücs G, Martin T, Distler O, Courvoisier DS; EUSTAR collaborators. Representativeness of systemic sclerosis patients in interventional randomized trials: an analysis of the EUSTAR database. Rheumatology (Oxford). 2022 Feb 2;61(2):743-755. doi: 10.1093/rheumatology/keab437. PMID: 33989387. (PDF)